CAJ | 학술논문

近十年来,随着免疫及分子生物学的发展,针对SLE免疫病理机制或相关靶点的生物靶向治疗药物取得了重大进展,以贝利单抗为标志的生物靶向治疗药物为SLE的治疗开辟了新的途径.目前有近20种SLE靶向治疗药物在进行临床前期或临床研究,根据其作用靶位的不同主要分为以下7类:B细胞特异性靶点药物、T细胞供刺激分子特异性靶点药物、细胞因子抑制剂、天然免疫靶位、耐受原、细胞表面受体抑制剂以及单核细胞趋化蛋白-1/单核细胞趋化因子CC配体2抑制剂、N-乙酰半胱氨酸等其他靶点药物.
근십년래,수착면역급분자생물학적발전,침대SLE면역병리궤제혹상관파점적생물파향치료약물취득료중대진전,이패리단항위표지적생물파향치료약물위SLE적치료개벽료신적도경.목전유근20충SLE파향치료약물재진행림상전기혹림상연구,근거기작용파위적불동주요분위이하7류:B세포특이성파점약물、T세포공자격분자특이성파점약물、세포인자억제제、천연면역파위、내수원、세포표면수체억제제이급단핵세포추화단백-1/단핵세포추화인자CC배체2억제제、N-을선반광안산등기타파점약물.
With the development of immunology and molecular-biology,great advances have been made in biological therapies targeted at the immunopathological mechanisms or directed against some targets in systemic lupus erythematosus (SLE) in the past decade.These biological agents,with belimumab as a representative,have offered a new approach to the treatment of SLE.At present,there are nearly 20 targeteddrugs for SLE that undergo preclinical research or clinical trials.According to the difference in action targets,they are mainly divided into seven categories:B-cell-targeted drugs,T-cell/costimulatory molecule-targeteddrugs,cytokine inhibitors,innate immunity-targeted drugs,tolerogens,inhibitors of cell surface receptors,and other targeted agents including monocyte chemoattractant protein 1/monocyte chemoattractant CC chemokineligand 2 inhibitors,N-acetyl cysteine,etc.